A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
Clinical trial NCT07687602 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07687602
- Sponsor
- AbbVie
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-06-30
- Primary completion
- 2031-08-01
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.